Acutaas Chemicals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 24%)
- Efficient capital deployment (ROCE 31.6%)
- Virtually debt-free
Concerns
- High premium to book value (P/B 15x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ACUTAAS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 39.91% | 39.91% | 35.98% | 35.97% | 35.96% | 35.96% |
| FII | 11.66% | 8.98% | 12.93% | 13.87% | 15.52% | 16.48% |
| DII | 7.58% | 6.80% | 14.81% | 19.93% | 20.23% | 18.31% |
| Public | 40.85% | 44.31% | 36.28% | 30.24% | 28.27% | 29.22% |
| Govt | — | — | — | — | 0.01% | 0.01% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 1.50 Per Share
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share
Dividend - Rs 3 Per Share
Annual General Meeting
Annual General Meeting
Dividend - Rs 3 Per Share
Latest News
All newsAcutaas subsidiary launches semiconductor plant in South Korea
*Acutaas subsidiary launches semiconductor plant in South Korea*. Indichem, a step-down subsidiary of Acutaas Chemicals, inaugurated a Semiconductor Materials Plant in Gongju, South Korea on August 28, 2026. This marks a strategic expansion into the high-growth semiconductor materials sector. The move strengthens Acutaas’ global footprint and technological capabilities. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #MEDIUMIMPACT #Semiconductors
Acutaas Chemicals issues general corporate updates
*Acutaas Chemicals issues general corporate updates.* The company filed routine updates with the NSE without disclosing specific financial or operational details. No **revenue**, **profit**, or **order** figures were provided. The filing appears to be procedural in nature. 📊 *STOCKS:* ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #corporate
Acutaas Chemicals publishes mandatory newspaper notice
*Acutaas Chemicals publishes mandatory newspaper notice.* This is a routine regulatory disclosure as per listing norms. **No financial or operational updates** were provided in the filing. Such publications are typically procedural. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #CorporateFiling
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹433 Cr 10.2% | ₹393 Cr 28.4% | ₹306 Cr 47.8% | ₹207 Cr 32.8% | ₹308 Cr 12.0% | ₹275 Cr 11.3% | ₹247 Cr 39.5% | ₹177 Cr |
| Op. Profit | ₹184 Cr 21.9% | ₹151 Cr 58.9% | ₹95 Cr 86.3% | ₹51 Cr 40.0% | ₹85 Cr 23.2% | ₹69 Cr 40.8% | ₹49 Cr 63.3% | ₹30 Cr |
| OPM | 42.0% 10.5% | 38.0% 22.6% | 31.0% 24.0% | 25.0% 10.7% | 28.0% 12.0% | 25.0% 25.0% | 20.0% 17.6% | 17.0% |
| Net Profit | ₹134 Cr 26.4% | ₹106 Cr 47.2% | ₹72 Cr 63.6% | ₹44 Cr 30.2% | ₹63 Cr 40.0% | ₹45 Cr 18.4% | ₹38 Cr 153.3% | ₹15 Cr |
| EPS (₹) | 16.09 22.0% | 13.19 49.5% | 8.82 63.0% | 5.41 29.1% | 7.63 39.0% | 5.49 20.4% | 4.56 166.7% | 1.71 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.3K Cr 33.0% | ₹1.0K Cr 40.4% | ₹717 Cr 16.2% | ₹617 Cr 18.7% | ₹520 Cr 52.5% | ₹341 Cr 42.1% | ₹240 Cr 0.4% | ₹239 Cr 27.1% | ₹188 Cr 17.5% | ₹160 Cr |
| Expenses | ₹859 Cr 10.8% | ₹775 Cr 31.6% | ₹589 Cr 19.5% | ₹493 Cr 18.8% | ₹415 Cr 59.6% | ₹260 Cr 31.3% | ₹198 Cr 1.0% | ₹196 Cr 24.8% | ₹157 Cr 14.6% | ₹137 Cr |
| Op. Profit | ₹480 Cr 106.9% | ₹232 Cr 81.3% | ₹128 Cr 4.1% | ₹123 Cr 17.1% | ₹105 Cr 31.3% | ₹80 Cr 90.5% | ₹42 Cr 0.0% | ₹42 Cr 35.5% | ₹31 Cr 34.8% | ₹23 Cr |
| OPM | 36.0% 56.5% | 23.0% 27.8% | 18.0% 10.0% | 20.0% 0.0% | 20.0% 16.7% | 24.0% 41.2% | 17.0% 5.6% | 18.0% 12.5% | 16.0% 14.3% | 14.0% |
| Other Income | ₹42 Cr 147.1% | ₹17 Cr 168.0% | ₹-25 Cr 725.0% | ₹4 Cr 33.3% | ₹3 Cr 200.0% | ₹1 Cr 50.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹3 Cr | ₹0 Cr |
| Interest | ₹3 Cr 50.0% | ₹6 Cr 0.0% | ₹6 Cr 200.0% | ₹2 Cr 66.7% | ₹6 Cr 0.0% | ₹6 Cr 0.0% | ₹6 Cr 20.0% | ₹5 Cr 66.7% | ₹3 Cr 0.0% | ₹3 Cr |
| Depreciation | ₹36 Cr 33.3% | ₹27 Cr 68.8% | ₹16 Cr 33.3% | ₹12 Cr 20.0% | ₹10 Cr 150.0% | ₹4 Cr 0.0% | ₹4 Cr 33.3% | ₹3 Cr 50.0% | ₹2 Cr 100.0% | ₹1 Cr |
| PBT | ₹483 Cr 123.6% | ₹216 Cr 163.4% | ₹82 Cr 26.8% | ₹112 Cr 23.1% | ₹91 Cr 26.4% | ₹72 Cr 105.7% | ₹35 Cr 0.0% | ₹35 Cr 25.0% | ₹28 Cr 47.4% | ₹19 Cr |
| Tax % | 26.0% 0.0% | 26.0% 36.6% | 41.0% 57.7% | 26.0% 23.8% | 21.0% 16.0% | 25.0% 19.0% | 21.0% 38.2% | 34.0% 2.9% | 35.0% 0.0% | 35.0% |
| Net Profit | ₹356 Cr 122.5% | ₹160 Cr 226.5% | ₹49 Cr 41.0% | ₹83 Cr 15.3% | ₹72 Cr 33.3% | ₹54 Cr 100.0% | ₹27 Cr 17.4% | ₹23 Cr 27.8% | ₹18 Cr 50.0% | ₹12 Cr |
| EPS (₹) | 43.51 124.5% | 19.38 234.1% | 5.8 49.3% | 11.43 15.8% | 9.87 15.2% | 8.57 34.5% | 13.08 17.8% | 11.1 82.0% | 61.67 53.5% | 40.17 |
| Div Payout | 6.0% 25.0% | 8.0% 69.2% | 26.0% 100.0% | 13.0% 13.3% | 15.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹41 Cr 0.0% | ₹41 Cr 10.8% | ₹37 Cr 2.8% | ₹36 Cr 0.0% | ₹36 Cr 12.5% | ₹32 Cr 220.0% | ₹10 Cr 0.0% | ₹10 Cr 400.0% | ₹2 Cr 0.0% | ₹2 Cr |
| Reserves | ₹1.6K Cr 27.1% | ₹1.3K Cr 99.2% | ₹637 Cr 14.2% | ₹558 Cr 14.8% | ₹486 Cr 260.0% | ₹135 Cr 33.7% | ₹101 Cr 40.3% | ₹72 Cr 28.6% | ₹56 Cr 51.4% | ₹37 Cr |
| Borrowings | ₹36 Cr 176.9% | ₹13 Cr 94.0% | ₹217 Cr 5325.0% | ₹4 Cr 300.0% | ₹1 Cr 99.3% | ₹137 Cr 132.2% | ₹59 Cr 9.3% | ₹54 Cr 22.7% | ₹44 Cr 63.0% | ₹27 Cr |
| Other Liabilities | ₹295 Cr 30.0% | ₹227 Cr 10.7% | ₹205 Cr 21.3% | ₹169 Cr 24.3% | ₹136 Cr 23.6% | ₹110 Cr 80.3% | ₹61 Cr 20.8% | ₹77 Cr 42.6% | ₹54 Cr 25.6% | ₹43 Cr |
| Total Liabilities | ₹2.0K Cr 28.1% | ₹1.5K Cr 41.3% | ₹1.1K Cr 42.9% | ₹767 Cr 16.4% | ₹659 Cr 59.6% | ₹413 Cr 78.0% | ₹232 Cr 8.9% | ₹213 Cr 37.4% | ₹155 Cr 42.2% | ₹109 Cr |
Assets | ||||||||||
| Fixed Assets | ₹745 Cr 30.7% | ₹570 Cr 33.5% | ₹427 Cr 64.9% | ₹259 Cr 26.3% | ₹205 Cr 10.2% | ₹186 Cr 118.8% | ₹85 Cr 7.6% | ₹79 Cr 146.9% | ₹32 Cr 14.3% | ₹28 Cr |
| CWIP | ₹332 Cr 155.4% | ₹130 Cr 4.0% | ₹125 Cr 316.7% | ₹30 Cr 900.0% | ₹3 Cr | ₹0 Cr 100.0% | ₹12 Cr 500.0% | ₹2 Cr 93.3% | ₹30 Cr 172.7% | ₹11 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹2 Cr 0.0% | ₹2 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 33.3% | ₹3 Cr 200.0% | ₹1 Cr |
| Other Assets | ₹907 Cr 7.0% | ₹848 Cr 56.2% | ₹543 Cr 13.8% | ₹477 Cr 6.0% | ₹450 Cr 100.0% | ₹225 Cr 69.2% | ₹133 Cr 1.5% | ₹131 Cr 44.0% | ₹91 Cr 33.8% | ₹68 Cr |
| Total Assets | ₹2.0K Cr 28.1% | ₹1.5K Cr 41.3% | ₹1.1K Cr 42.9% | ₹767 Cr 16.4% | ₹659 Cr 59.6% | ₹413 Cr 78.0% | ₹232 Cr 8.9% | ₹213 Cr 37.4% | ₹155 Cr 42.2% | ₹109 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹292 Cr 147.5% | ₹118 Cr 5.6% | ₹125 Cr 89.4% | ₹66 Cr 650.0% | ₹-12 Cr 142.9% | ₹28 Cr 3.7% | ₹27 Cr 80.0% | ₹15 Cr 87.5% | ₹8 Cr 72.4% | ₹29 Cr |
| Investing CF | ₹-266 Cr 18.8% | ₹-224 Cr 38.6% | ₹-365 Cr 1006.1% | ₹-33 Cr 72.7% | ₹-121 Cr 19.8% | ₹-101 Cr 320.8% | ₹-24 Cr 14.3% | ₹-21 Cr 16.0% | ₹-25 Cr 31.6% | ₹-19 Cr |
| Financing CF | ₹4 Cr 98.5% | ₹261 Cr 9.2% | ₹239 Cr 2091.7% | ₹-12 Cr 108.6% | ₹140 Cr 94.4% | ₹72 Cr | ₹0 Cr 100.0% | ₹6 Cr 60.0% | ₹15 Cr 314.3% | ₹-7 Cr |
| Net Cash Flow | ₹30 Cr 80.8% | ₹156 Cr 15700.0% | ₹-1 Cr 105.0% | ₹20 Cr 150.0% | ₹8 Cr 900.0% | ₹-1 Cr 133.3% | ₹3 Cr | ₹0 Cr 100.0% | ₹-2 Cr 166.7% | ₹3 Cr |
| Free Cash Flow | ₹-36 Cr 52.6% | ₹-76 Cr 51.0% | ₹-155 Cr 400.0% | ₹-31 Cr 32.6% | ₹-46 Cr 40.3% | ₹-77 Cr 1383.3% | ₹6 Cr 185.7% | ₹-7 Cr 56.3% | ₹-16 Cr 260.0% | ₹10 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99d 5.7% | 105d 0.0% | 105d 22.8% | 136d 18.3% | 115d 10.9% | 129d 50.0% | 86d 25.9% | 116d 19.6% | 97d 16.9% | 83d |
| Inventory Days | 149d 25.2% | 119d 14.4% | 139d 6.1% | 131d 12.7% | 150d 22.0% | 123d 16.9% | 148d 55.8% | 95d 6.7% | 89d 17.1% | 76d |
| Days Payable | 99d 3.9% | 103d 13.4% | 119d 24.2% | 157d 0.6% | 158d 8.1% | 172d 17.8% | 146d 13.1% | 168d 9.1% | 154d 4.1% | 148d |
| Cash Conv. Cycle | 149d 23.1% | 121d 3.2% | 125d 12.6% | 111d 3.7% | 107d 33.8% | 80d 9.1% | 88d 104.7% | 43d 38.7% | 31d 181.8% | 11d |
| Working Capital Days | 116d 5.7% | 123d 53.8% | 80d 42.4% | 139d 1.4% | 141d 176.5% | 51d 50.0% | 34d 21.4% | 28d 56.3% | 64d 39.1% | 46d |
| ROCE | 32.0% 60.0% | 20.0% 25.0% | 16.0% 23.8% | 21.0% 12.5% | 24.0% 27.3% | 33.0% 22.2% | 27.0% 20.6% | 34.0% 10.5% | 38.0% | — |
Source: Screener.in · Lower days = better efficiency
About Acutaas Chemicals Limited
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
HealthcarePharmaceuticals & Biotechnology